Under the transaction, Eisai earns $65m upfront payment in addition to probable milestone-based contingent payments.
The new drug application (NDA) for Targretin was transferred to Valeant, which will be responsible for all regulatory requirements related to the product in the US.
Eisai holds Targretin rights outside of the US.
Targretin (bexarotene) capsules and Targretin gel are indicated for patients with skin problems associated with cutaneous T-cell lymphoma (CTCL) when at least one systemic therapy has not worked.